Drug intelligence / Profile preview

ADS-4101

Development stage: Unknown
Lead developer: Supernus Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**ADS-4101** is an investigational, chrono-synchronous modified-release formulation of **lacosamide**, a sodium channel inhibitor with anti-epileptic properties, developed by **Adamas Pharmaceuticals** (now a subsidiary of **Supernus Pharmaceuticals**). Designed for once-nightly dosing (up to 600 mg), it aims to deliver high concentrations of lacosamide during daytime hours when partial-onset seizures in epilepsy patients predominantly occur, potentially improving efficacy and tolerability over immediate-release lacosamide (marketed as **Vimpat**).[1][2][3][13]

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on ADS-4101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADS-4101.

Explore the full profile